Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA-001 in Pancreatic Exocrine Insufficiency
NCT00400842Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2007
- Primary completion
- Aug 2009
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pancrelipase in pancreatic exocrine insufficiency (EPI) (3 arms), sponsored by Abbott Laboratories. Primary endpoint: Change in Coefficient of Fat Absorption at 7 days. Started May 2007; status: completed.
02
Drugs
pancrelipase
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT00400842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400842.